asco lung cancer roundtable - nsclc trial updates: checkmate 227 opdivo yervoy combination today
Published 3 years ago • 211 plays • Length 11:42Download video MP4
Download video MP3
Similar videos
-
11:48
asco lung cancer roundtable - nsclc trial updates: checkmate 9la opdivo and yervoy with chemo vs
-
8:13
checkmate 816: combining chemo and opdivo - asco lung review 2022
-
9:40
asco 2018 - checkmate 227 - combinations of nivolumab and ipilimumab, or nivolumab and and chemo
-
16:41
asco lung cancer roundtable - trial updates in nsclc - adaura trial and post surgery egfr mutation
-
8:35
asco lung cancer roundtable - nsclc - the cityscape trial: anti tigit & immune checkpoint inhibitor
-
10:02
unresectable nsclc - does checkmate 227's suggestion of an immunotherapy combination of yervoy and o
-
4:42
asco lung cancer roundtable - new combinations chemo immunotherapy for extensive stage sclc
-
9:21
asco lung cancer roundtable - nsclc - new potential treatments for met and ret positive nsclc
-
11:30
asco 2021 lung recap: surgical outcomes & checkmate 816: nivolumab in early stage nsclc
-
8:43
asco lung cancer roundtable - nsclc - enhertu and the potential for treatment of her2 positive nsclc
-
11:58
asco lung cancer roundtable - mesothelioma updates
-
8:43
asco lung cancer roundtable - gronberg study - chest radiation with chemo for limited stage sclc
-
12:34
asco lung cancer roundtable - nsclc - the sindas trial: addition of sbrt to a systemic tki for egfr
-
3:25
checkmate 816: neoadjuvant nivolumab chemotherapy for nsclc - onctalk lung 2023
-
4:56
dual immune checkpoint blockade with or without chemotherapy - lung cancer onctalk 2022
-
6:38
asco 2019 lung cancer round table: new cancer research: important results from afatinib trial
-
6:32
asco 2019 lung cancer round table - new cancer research: long term outcomes of pembrolizumab